A closely watched FDA advisory committee has recommended that six popular peptides be added to the federal list of bulk drug substances that may be used by traditional compounding pharmacies.
The Pharmacy Compounding Advisory Committee met on July 23–24, 2026, to consider seven peptide-related substances. The committee voted in favor of recommending BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon for inclusion on the Section 503A Bulks List. Emideltide—also known as delta sleep-inducing peptide, or DSIP—was not recommended.
The votes represent an important potential change in the regulatory direction for compounded peptides. They do not, however, make any of these substances FDA-approved drugs or immediately authorize pharmacies to begin compounding them.
Which peptides received favorable recommendations?
- BPC-157
- KPV
- TB-500
- MOTS-c
- Semax
- Epitalon
The committee voted against recommending Emideltide (DSIP).
Each substance was reviewed in connection with specific nominated uses. A favorable recommendation for the compounding list should not be interpreted as FDA endorsement of the much broader wellness, recovery, anti-aging, or performance claims frequently seen online.
What is the Section 503A Bulks List?
Section 503A of the Federal Food, Drug, and Cosmetic Act provides a pathway for state-licensed pharmacies to prepare patient-specific compounded medications when certain legal conditions are met. A substance without an applicable United States Pharmacopeia monograph or component of an FDA-approved drug generally must appear on the 503A Bulks List before it can be used in this type of compounding.
Compounded drugs are not FDA-approved. The agency does not evaluate them for safety, effectiveness, or manufacturing quality before they reach patients in the same way it evaluates approved medicines.
What changed—and what did not?
The advisory committee’s votes are nonbinding recommendations. FDA must still decide whether to follow them and complete a formal rulemaking process before the federal list changes.
That process may include publication of a proposed rule, a public-comment period, review of those comments, and a final rule. It can take months or longer.
For consumers, the immediate takeaway is simple: the committee vote is significant, but it did not instantly legalize or approve these peptides.
Why FDA scientists opposed the recommendations
FDA career scientists recommended against adding the reviewed peptides, citing limited clinical evidence, gaps in human safety data, uncertain product characterization, and a lack of proven long-term effectiveness for the nominated uses.
For BPC-157, for example, FDA staff said the available studies were small, short, and exploratory. Similar concerns were raised about the evidence supporting the other substances.
The committee ultimately placed greater weight on potential patient access, clinician judgment, pharmacy oversight, and the possibility that a regulated compounding pathway could be safer than products obtained from unverified online sellers.
Questions about the panel’s composition
The votes also attracted scrutiny because several recently appointed committee members have professional connections to wellness clinics, peptide prescribing, consulting, or compounding businesses. That does not by itself invalidate their votes, but it is relevant context when evaluating a closely divided recommendation.
What happens next?
FDA will consider the committee’s advice as it determines whether to begin or complete rulemaking for the six recommended substances. Until formal action is taken, consumers and clinicians should not assume the 503A Bulks List has changed.
A second advisory committee meeting is expected before the end of February 2027 to consider five additional peptides.
What consumers should know
- A recommendation for compounding is not FDA drug approval.
- Evidence varies substantially among peptides and proposed uses.
- Products obtained from unverified online sellers may have uncertain identity, strength, purity, and sterility.
- A prescription does not eliminate the need to discuss potential risks, alternatives, and evidence with a qualified clinician.
- Patients should ask which pharmacy prepares the product and how that pharmacy tests its ingredients and finished preparations.
The bottom line
The July 2026 votes are one of the most consequential developments in U.S. peptide policy in recent years. They may eventually create a clearer path for patient-specific access through licensed compounding pharmacies. At the same time, the votes do not resolve the scientific questions surrounding safety and effectiveness.
For now, this is an important recommendation—not a final approval.
Sources and further reading
- FDA: July 23–24, 2026 Pharmacy Compounding Advisory Committee meeting
- Associated Press: FDA panel recommendations and scientific concerns
- FDA: Human Drug Compounding
This article is for general educational purposes and does not constitute medical or legal advice. Regulatory status may change as FDA completes its review.
